Reported 1 day ago
Scholar Rock Holding Corp. (NASDAQ:SRRK) is gaining attention for its lead drug candidate, apitegromab, which aims to treat spinal muscular atrophy (SMA). Despite a recent drop in stock value, analyst optimism remains high ahead of a potential U.S. launch in Q3 2025, with projections for significant market potential exceeding $2 billion. Jefferies analyst Amy Li has set a $50 price target, highlighting the drug's commercial viability across various SMA types. However, some risks persist regarding FDA approval timelines.
Source: YAHOO